Related Experiment Video
Updated: Aug 26, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
The Benefits of Adding Non-Antimuscarinic Pharmaceuticals in Combination With Beta-3 Agonists for Overactive Bladder
Felicity Smith1, Charlotte Phelps1, Christian Moro1
1Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia.
Introduction:
Antimuscarinics, as the current first-line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta-3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and prescription compliance. Of interest is the growing potential for non-antimuscarinics to be incorporated in combination therapies alongside these beta-3 agonists.
Methods:
Following PRISMA guidelines, searches were undertaken in PubMed, EMBASE and Cochrane Library for randomized controlled trials of patients with OAB, comparing monotherapy beta-3 agonist with beta-3 in combination with non-antimuscarinic pharmaceuticals. Risk of bias was performed using the Cochrane Risk of Bias Tool 1.
Result:
Seven trials with 719 participants were included. All studies utilized mirabegron as the beta-3 agonist. Two studies analyzed the effectiveness of mirabegron in combination with a second-line treatment, whereas the other five combined third-line treatment options. Benefits were reported in studies where beta-3 agonists were used in conjunction with botulinum toxin, acupuncture, nerve stimulation, tadalafil, and vitamin D3.
Conclusion:
There appear to be therapeutic benefits supporting the use of several different interventions in combination with a beta-3 agonist for the alleviation of overactive bladder symptoms. However, further research is needed due to limited evidence and heterogeneity.
Related Concept Videos
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-Acting Cholinergic Agonists: Pharmacological Actions